Telix Pharmaceuticals Limited
TLX
$9.98
-$0.13-1.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -65.50% | -4.07% | 971.69% | 329.12% | 200.69% |
| Total Depreciation and Amortization | 162.04% | 104.70% | 18.20% | 20.18% | 20.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 158.77% | 208.33% | 0.25% | -29.44% | -56.72% |
| Change in Net Operating Assets | -94.04% | -94.04% | -94.04% | -187.14% | -3,140.78% |
| Cash from Operations | -32.64% | 75.46% | 63.48% | 151.92% | 373.77% |
| Capital Expenditure | -76.10% | -63.44% | -47.20% | -46.80% | -43.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -1,327.32% | -14,161.52% | -2,292.06% | -2,509.49% | -2,813.53% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -220.60% | -367.16% | -507.21% | -735.55% | -126,176.65% |
| Cash from Investing | -604.67% | -892.22% | -434.60% | -503.09% | -684.40% |
| Total Debt Issued | 11,865.38% | 11,810.22% | 11,286.82% | 5,772.44% | -0.70% |
| Total Debt Repaid | -141.43% | -138.08% | -23.13% | -33.21% | -47.59% |
| Issuance of Common Stock | -75.20% | -83.25% | -87.38% | -55.03% | -7.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1,483.07% | -360.15% | -- | -- | -- |
| Cash from Financing | 8,225.78% | 9,294.13% | 6,152.79% | 3,386.35% | -12.12% |
| Foreign Exchange rate Adjustments | 4,048.45% | 11,929.52% | 2,653.06% | 2,232.35% | -413.89% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,559.82% | 25,942.45% | 7,904.42% | 3,344.30% | -275.95% |